List of Excipients in Branded Drug HIBICLENS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	FD&C RED NO. 40
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	GLUCONOLACTONE
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	ISOPROPYL ALCOHOL
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	LAURAMINE OXIDE
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	POLOXAMER 237

Last updated: September 3, 2026

ecutive summary: Hibiclens is a consumer and healthcare antiseptic wash containing 4% chlorhexidine gluconate (CHG). Its commercial value is driven less by active-ingredient exclusivity than by brand recognition, institutional purchasing, skin tolerability, packaging, regulatory compliance, and channel access. The strongest excipient opportunities are fragrance-free and dye-free variants, improved foam and rinseability, reduced skin dryness, preservative and microbial-control systems, concentrated institutional formats, and packaging that limits contamination and dosing waste. Core CHG composition patents are unlikely to provide meaningful protection because the active ingredient and conventional 4% wash formulations have been commercialized for decades.

Hibiclens Excipient Strategy and Commercial Opportunities

What is Hibiclens and how is it regulated?

Hibiclens is a topical antiseptic skin cleanser containing 4% chlorhexidine gluconate. The product is used for handwashing, preoperative skin cleansing, and general antimicrobial skin cleansing, subject to label limitations and warnings. Mölnlycke Health Care markets Hibiclens in the United States. The product is sold through hospitals, pharmacies, retailers, e-commerce channels, and occupational-health distributors.

The US product is regulated as an over-the-counter topical antiseptic rather than as a conventional prescription drug. Its regulatory position differs from a new chemical entity protected through an approved New Drug Application and Orange Book patent listings. FDA’s antiseptic rules and monograph-related actions govern the regulatory framework, while the product’s specific labeling and manufacturing controls remain important commercial assets.[1,2]

Core product profile

Attribute	Hibiclens position
Active ingredient	Chlorhexidine gluconate, 4%
Dosage form	Topical liquid wash
Primary routes	Cutaneous use; not for injection, oral use, or mucosal use
Main channels	Hospitals, retail pharmacies, mass retail, e-commerce
Principal manufacturer/marketer	Mölnlycke Health Care
Regulatory category	OTC topical antiseptic cleanser
Orange Book relevance	Generally limited compared with NDA products
Biosimilar exposure	None
Principal commercial defenses	Brand, distribution, institutional contracts, formulation know-how, packaging, clinical familiarity

Hibiclens is not a biologic and has no biosimilar pathway. Generic competition is possible through alternative CHG wash products, private-label products, hospital formulations, and competing antiseptic products rather than through biosimilar substitution.

What excipients are used in Hibiclens?

Public product labeling identifies Hibiclens as a 4% CHG formulation with excipients that include water and formulation-supporting ingredients such as isopropyl alcohol, fragrance, glycerin, and colorant, depending on the marketed configuration and jurisdiction.[3] Exact excipient composition should be confirmed against the current package insert, Drug Facts label, and regulatory filing for each SKU.

The excipient system has to solve five formulation problems:

1. Maintain CHG stability and antimicrobial activity.
2. Deliver adequate wetting and coverage on skin.
3. Remove soil and transient organisms without excessive irritation.
4. Preserve the product against microbial contamination.
5. Remain compatible with packaging, pumps, labels, and hospital dispensing systems.

CHG is a cationic bisbiguanide. Its compatibility profile is therefore important. Anionic surfactants and certain anionic polymers can bind or neutralize cationic antiseptics, potentially reducing antimicrobial performance. Formulators must evaluate every surfactant, thickener, fragrance component, colorant, preservative, and packaging contact material for CHG compatibility.

Likely excipient functions

Excipient category	Commercial function	Principal risk
Purified water	Vehicle	Microbial contamination and water-quality variation
Alcohol	Solvency, quick drying, sensory effect	Dryness, flammability, packaging compatibility
Humectant such as glycerin	Reduces perceived dryness	May alter viscosity and rinse profile
Fragrance	Consumer acceptance and product identity	Sensitization and hospital restrictions
Colorant	Brand recognition and product differentiation	Allergy concerns and dye-free demand
Surfactant system	Soil removal and foam	CHG binding, irritation, reduced antimicrobial activity
Rheology modifier	Dosing control and cling time	Dispensing problems and compatibility
Preservative system	Microbial protection	CHG interaction and regulatory review

What excipient improvements could create new Hibiclens products?

The most attractive opportunities are line extensions that preserve the 4% CHG active concentration while improving tolerability, usability, or channel fit.

Fragrance-free and dye-free Hibiclens

A fragrance-free, dye-free product would address hospitals, sensitive-skin consumers, occupational-health programs, and institutional buyers seeking lower allergen exposure. The commercial case is strong because fragrance and color do not contribute to antimicrobial activity. Removing them could simplify the formula and reduce potential sensitization concerns.

A successful variant would require comparative testing for:

• CHG assay and degradation products;
• antimicrobial activity;
• viscosity and dispensing;
• color and odor acceptance;
• preservative performance;
• packaging compatibility;
• skin irritation and sensitization.

The product could be positioned for surgical centers, dermatology clinics, oncology settings, dialysis providers, and consumers with recurrent skin sensitivity. The principal risk is loss of the visual and sensory cues associated with the established Hibiclens brand.

Barrier-supportive and low-dryness formulations

Repeated CHG use can produce dryness or irritation in some users. A formulation using a carefully selected humectant, emollient, or skin-conditioning system could expand use among healthcare workers and patients who need repeated cleansing.

The technical constraint is that lipidic or anionic ingredients can affect CHG availability and antimicrobial performance. Any barrier-supportive excipient must be evaluated for:

• adsorption of CHG;
• reduced kill kinetics;
• residue on skin;
• interference with gloves or surgical drapes;
• increased microbial growth risk;
• changes in rinseability.

A lower-dryness formulation should not be marketed as more protective unless the relevant clinical and regulatory evidence supports that claim.

Improved foam and dosing control

Pump foamers, metered-dose pumps, and controlled-viscosity liquids can reduce product waste and improve coverage. These changes create commercial value in hospitals, where dispensing consistency and per-use cost influence purchasing decisions.

Potential formats include:

• ready-to-use liquid in a metered pump;
• foaming pump presentation;
• single-use sachets or packets;
• larger refill containers for controlled dispensers;
• travel-size containers for retail;
• premeasured surgical or patient-decolonization kits.

Foam does not automatically improve antimicrobial performance. The relevant metrics are dose delivered, skin coverage, contact time, rinseability, and user adherence.

Low-residue and fast-rinse systems

A low-residue formulation could improve patient acceptance and reduce complaints involving tackiness, odor, or staining. This may be valuable in home-use decolonization programs and high-frequency healthcare applications.

The formulation must preserve the substantivity associated with CHG while limiting visible residue. Excessive reduction in skin retention could weaken the product’s practical value. Development should compare residual CHG on skin, antimicrobial persistence, user preference, and irritation.

What formulation patents protect Hibiclens?

Publicly available commercial information does not establish a current, enforceable patent estate that broadly protects the basic 4% CHG wash composition. Chlorhexidine gluconate antiseptic washes and related formulations have been marketed for many years, making basic composition patents vulnerable to expiration, invalidity, or narrow claim scope.

The more relevant IP categories are likely to be:

• dispensing pumps and foam-generating systems;
• single-use packaging;
• formulation-specific stability improvements;
• manufacturing and filling processes;
• preservative systems;
• low-irritation surfactant combinations;
• preoperative or decolonization kits;
• combination products with wipes, gowns, or applicators;
• trademarks and trade dress;
• confidential manufacturing and quality-control know-how.

How strong is the Hibiclens patent estate?

The likely strength profile is mixed:

IP category	Expected strength	Commercial impact
Basic 4% CHG wash composition	Low to moderate	Limited exclusivity due to age of technology
Brand and trade dress	High if properly maintained	Important in retail and hospital procurement
Packaging and dispensing	Moderate	Can delay direct copying of user experience
Manufacturing know-how	Moderate to high	Difficult to assess publicly; relevant to quality and scale
Method-of-use claims	Variable	Narrow claims may support specific clinical programs
Formulation improvements	Moderate	Stronger if supported by comparative data
Regulatory data and labeling	Moderate	Supports compliant commercialization but does not equal patent exclusivity

A competitor can generally avoid a formulation patent by changing the surfactant, fragrance, rheology modifier, preservative, package, or dispensing system, provided it maintains CHG activity and meets regulatory requirements.

When does Hibiclens lose exclusivity?

Hibiclens does not have a conventional small-molecule patent cliff comparable to a branded prescription medicine. Its commercial exclusivity is based primarily on trademark protection, brand loyalty, distribution, institutional contracts, manufacturing scale, regulatory compliance, and product familiarity.

The basic CHG technology is mature. Competitors already sell 4% CHG cleansers, including healthcare and private-label products. Consequently, the relevant “loss of exclusivity” event is not a single patent expiration date. It is the erosion of brand differentiation through:

• hospital conversion to lower-cost CHG products;
• private-label sourcing;
• new dispensing systems;
• fragrance-free competitor launches;
• institutional decolonization protocols;
• supply disruptions;
• procurement consolidation;
• consumer migration to online alternatives.

What is the Orange Book status of Hibiclens?

Hibiclens is not best analyzed through the Orange Book framework used for approved prescription drugs with listed patents and approved exclusivity. OTC antiseptic products are governed through FDA’s nonprescription drug rules and product-specific labeling requirements. A standard Orange Book Paragraph IV pathway is therefore not the primary competitive mechanism for Hibiclens.

A competitor would more commonly commercialize an alternative CHG cleanser by complying with applicable FDA requirements, using an appropriate regulatory pathway, and avoiding trademark, trade dress, formulation, packaging, or method-of-use claims.

Which companies compete with Hibiclens?

The competitive field includes branded CHG cleansers, hospital private-label products, surgical skin-preparation products, and non-CHG antiseptics.

Competitor category	Examples	Competitive basis
4% CHG washes	Betasept, Dyna-Hex and other institutional products	Price, contracts, availability
CHG-alcohol surgical preps	ChloraPrep and comparable products	Rapid preparation and procedure-specific use
Povidone-iodine products	Betadine and hospital alternatives	Broad familiarity and lower-cost procurement
Private-label CHG	Hospital and distributor brands	Margin, tender pricing, customization
Antimicrobial wipes	CHG-impregnated cloth products	Compliance, convenience, protocol integration

ChloraPrep should not be treated as a direct formulation substitute for Hibiclens. It is generally a procedure-focused skin preparation combining CHG with alcohol, while Hibiclens is a wash product with different use instructions, contact-time expectations, packaging, and safety considerations.

What generic entry risks exist for Hibiclens?

Generic and private-label entry risk is meaningful because the active ingredient is established, the dosage form is simple, and consumers and hospitals can compare products by concentration and price.

The main entry barriers are operational rather than purely patent-based:

• demonstrating consistent CHG concentration;
• controlling microbial quality in a water-based product;
• maintaining preservative effectiveness;
• proving packaging compatibility;
• meeting labeling and warning requirements;
• securing hospital contracts;
• maintaining supply continuity;
• avoiding irritating or incompatible excipient systems;
• establishing acceptable shelf life.

A lower-cost competitor can gain share without replicating the full Hibiclens formula. It may use a different fragrance, surfactant, viscosity, package, or color system. The most defensible commercial position is therefore a combination of trusted brand, validated performance, differentiated tolerability, and institutional protocol integration.

What formulation and manufacturing IP barriers matter most?

Manufacturing controls can provide more practical protection than expired composition patents. Key areas include:

CHG compatibility

Cationic CHG can interact with anionic materials. A manufacturer with a validated surfactant and excipient system may achieve better antimicrobial performance and stability than a low-cost entrant.

Microbial control

Water-based antiseptic washes require robust raw-material controls, validated preservation, hygienic filling, and container-closure integrity. USP microbial limits and antimicrobial effectiveness testing are central quality considerations.[4,5]

Packaging

The package must prevent leakage, maintain dose accuracy, withstand alcohol exposure if present, and avoid adsorption or extraction involving the formulation. Pump performance is especially important for institutional products.

Scale and supply

Large-volume manufacturing, quality release, and hospital distribution create barriers that are difficult for small entrants to replicate. Supply reliability can influence hospital contracts as much as nominal price.

What licensing deals and commercial partnerships are relevant?

Hibiclens is commercially linked to Mölnlycke’s healthcare distribution platform. Publicly disclosed information does not establish a major current licensing transaction that transfers broad rights to the underlying 4% CHG formulation.

The most realistic partnership opportunities involve:

• private-label supply for hospital systems;
• co-branded surgical or decolonization kits;
• pump and dispenser manufacturers;
• contract manufacturing;
• pharmacy and e-commerce distribution;
• home-health and dialysis channels;
• clinical-protocol partnerships;
• international registration and distribution.

For an excipient supplier, the most attractive entry point is a formulation or package improvement that can be supplied under a quality agreement without requiring replacement of the established active ingredient.

What regulatory and clinical claims can support commercial differentiation?

FDA has identified risks associated with CHG skin exposure, including serious allergic reactions, and labeling must address appropriate use and avoidance of sensitive sites.[2,3] A new excipient strategy cannot create unsupported claims such as “safer,” “hypoallergenic,” or “clinically superior” without appropriate evidence.

Potentially supportable claims depend on testing and regulatory review, including:

• fragrance-free;
• dye-free;
• metered dose;
• reduced residue;
• improved rinseability;
• lower perceived dryness;
• compatible with a specified dispenser;
• designed for a specified institutional protocol.

Claims involving reduced infection rates, superior decolonization, or improved clinical outcomes require clinical substantiation and may change the regulatory analysis.

What are the highest-value commercial opportunities?

The strongest opportunities rank as follows:

1. Fragrance-free and dye-free 4% CHG wash for hospitals and sensitive-skin users.
2. Metered-dose or foam delivery that reduces waste and improves protocol adherence.
3. Low-residue, lower-dryness formulation supported by comparative tolerability data.
4. Single-use and travel formats for outpatient, home-health, and decolonization programs.
5. Institutional refill systems with tamper control and usage tracking.
6. CHG cleansing kits combining wash, wipes, instructions, and disposable accessories.
7. International formulations adapted to local excipient restrictions and packaging requirements.

Revenue exposure is likely concentrated in recurring institutional volume, retail replenishment, and protocol-driven use. No reliable public disclosure establishes Hibiclens-specific revenue, so commercial assessment should rely on channel sales, contract wins, SKU expansion, and share within the broader CHG cleanser market rather than a standalone public revenue figure.

Key Takeaways

• Hibiclens is a mature 4% chlorhexidine gluconate antiseptic wash.
• Its principal defenses are brand, distribution, institutional procurement, validated manufacturing, and packaging rather than a likely active patent cliff.
• The most promising excipient strategies are fragrance-free, dye-free, lower-dryness, low-residue, and improved-foaming formulations.
• Anionic excipients require careful compatibility testing because CHG is cationic.
• Pump, foam, single-use, and refill packaging can create commercial differentiation without changing the active ingredient.
• Paragraph IV litigation and biosimilar competition are not the central risks.
• Private-label 4% CHG products and hospital procurement substitution represent the main entry threats.
• Formulation know-how, microbial control, packaging performance, and institutional contracts may be more valuable than legacy composition patents.

FAQs

Can a new excipient make Hibiclens more effective?

Yes, but only if the excipient improves coverage, contact time, skin retention, or user adherence without reducing CHG availability. Any efficacy claim requires comparative antimicrobial and, where appropriate, clinical evidence.

Is a fragrance-free Hibiclens formulation commercially viable?

Yes. A fragrance-free and dye-free version could target hospitals, sensitive-skin consumers, oncology care, dialysis, and home-health use. The main development issue is preserving product identity and user acceptance after removing sensory cues.

Can a competitor patent a new 4% chlorhexidine wash?

Possibly, if the formulation includes a novel and non-obvious excipient combination, stability solution, delivery system, or use supported by adequate technical evidence. A patent on the general concept of a 4% CHG wash would face substantial prior-art risk.

Does Hibiclens face biosimilar competition?

No. Hibiclens contains a synthetic antiseptic active ingredient and is not a biologic. Competition comes from generic, private-label, and alternative antiseptic products.

Which package format offers the best commercial opportunity?

Metered-dose pumps and single-use formats offer the clearest differentiation. They can reduce waste, improve dosing consistency, support infection-control protocols, and create device or packaging IP opportunities.

References

1. U.S. Food and Drug Administration. (2017). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 82 Fed. Reg. 7644.

2. U.S. Food and Drug Administration. (2022). FDA warns about rare but serious allergic reactions with chlorhexidine gluconate. FDA Drug Safety Communication.

3. DailyMed. (n.d.). Hibiclens chlorhexidine gluconate 4% liquid: Drug Facts and labeling. National Library of Medicine.

4. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

5. United States Pharmacopeia. (2024). General chapters <61> and <62>: Microbiological examination of nonsterile products. United States Pharmacopeial Convention.